Stephens & Co. Maintains Overweight on Avid Bioservices, Lowers Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
Stephens & Co. analyst Jacob Johnson maintains an Overweight rating on Avid Bioservices (CDMO) but lowers the price target from $15 to $12.

March 11, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Avid Bioservices' price target was reduced from $15 to $12 by Stephens & Co., although the Overweight rating was maintained.
The reduction in price target by Stephens & Co. reflects a revised outlook on Avid Bioservices, potentially due to updated financial analysis or market conditions. However, maintaining the Overweight rating indicates a continued positive view on the stock's future performance. This mixed signal could lead to short-term uncertainty among investors, but the maintained positive rating suggests underlying confidence in the company's fundamentals.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100